Opioid Use Disorder in the Emergency Department: CTN 0069: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Opioid Use Disorder in the Emergency Department: CTN 0069 (NCT03023930), a na na study. The primary outcome is Implementation (Considered the Primary Outcome).

2. Clinical Question

The study also aimed to evaluate patient engagement in formal addiction treatment at 30 days. That aim is distinct from the registry’s stated primary implementation outcome: the rate of ED-initiated treatment with referral. Keeping these questions separate matters because a change in the delivery of an intervention and a change in subsequent patient engagement are different outcomes and can require different measures and analyses. The registry lists ED Organizational Readiness to Change Assessment (ORCA) Score as a secondary outcome, but does not report its results. The record therefore establishes the questions and implementation context, but does not provide enough outcome data to assess the magnitude or precision of any observed change.

3. Trial Design

NCT03023930, titled Opioid Use Disorder in the Emergency Department: CTN 0069, is listed as a completed study sponsored by Yale University. The registry records a start date of 2017-04-03, a primary completion date of 2021-07-16, and total enrollment of 1731. Its phase and allocation are listed as NA. The masking entry is NONE, and the study model is SINGLE GROUP.

The intervention entries are Standard Dissemination Practice and Implementation Facilitation (IF). The arm description says that standard dissemination practice is evaluated in comparison with implementation facilitation. The adverse-event entries use the labels Baseline Evaluation Period Cohort and IF Evaluation Period. These names indicate periods of evaluation, not evidence of randomized assignment. The registry explicitly warns that this is not a randomized comparison and that the arms are not a like-for-like control comparison.

That distinction is central to interpretation. In a randomized trial, assignment is designed to make comparison groups comparable on average. In a comparison across periods, differences in outcomes could reflect the implementation approach, but they could also reflect changes over time, differences in who was observed, or other contextual factors. Whether and how such influences were measured or adjusted is not reported in the registry record.

The primary outcome is described as implementation, measured by the rate of ED-initiated BUP therapy with referral for ongoing MAT, with a timeframe of 12 months. The brief study description also identifies patient engagement in formal addiction treatment at 30 days as an aim. The record lists 21 outcome measures and 2 analyses, but does not provide enough detail to determine the analysis populations, analytic models, or how each outcome was handled. The registry reports an ORCA Score as a secondary outcome. Further details about sites, recruitment procedures, and implementation fidelity are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Baseline characteristics were not collected for providers.

6. Primary Endpoint

The registry lists the primary outcome as Implementation (Considered the Primary Outcome), measured over 12 months.

The primary outcome is labeled Implementation and is described as the rate of emergency department-initiated buprenorphine/naloxone (BUP) therapy with referral for ongoing medication-assisted treatment (MAT). Its stated timeframe is 12 months. This endpoint focuses on whether the intended care process was put into practice: ED initiation of BUP together with a referral for continued treatment. It is therefore an implementation measure, rather than a direct measure of later patient engagement or clinical status.

A rate can describe how often a defined action occurs within a defined population or opportunity. To interpret it, readers need to know the numerator, the denominator, and how both were defined. For example, the record would need to clarify which ED encounters or patients were eligible, how repeat encounters were treated, and what counted as a completed referral. Those operational details and the observed primary outcome counts are not reported in the registry record.

The endpoint is relevant to the stated implementation question because it concerns delivery of the targeted ED practice. It is distinct from the brief description’s patient-engagement aim at 30 days: initiating treatment and making a referral do not by themselves describe whether a patient later engaged in formal addiction treatment. The registry record does not report the primary outcome estimate, uncertainty interval, or a comparison result. Consequently, the endpoint definition can be described, but its observed magnitude and precision cannot be assessed from the posted results.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies the primary outcome as a count-based implementation measure: the rate of ED-initiated BUP therapy with referral for ongoing MAT. The outcome is described as evaluated over 12 months. A rate usually combines a count of qualifying events or participants with a denominator representing the population or opportunities in which those events could occur. The exact numerator and denominator definitions are not reported in the registry record, so the operational meaning of the rate cannot be reconstructed in detail.

What a count can and cannot show

A count reports how many participants experienced a defined event. It is straightforward to understand, but it does not by itself describe the chance of the event unless the relevant population or denominator is also known. Rates or proportions allow comparisons across groups with different denominators, provided that the groups and outcome definitions are suitable for comparison. The posted primary outcome results do not include counts, denominators, or a rate estimate, so no outcome magnitude can be interpreted from the record.

For binary outcomes, a common analysis estimates the event proportion in each group and then compares those proportions. The choice of effect measure depends on the question and analysis plan. A confidence interval describes the range of effect values reasonably compatible with the data under the statistical model; a narrower interval indicates greater precision, while a wider interval indicates more uncertainty. No primary confidence interval or comparative estimate is reported in the registry record.

Why the comparison structure matters

The registry labels the model SINGLE GROUP and allocation NA, and identifies baseline and IF evaluation periods. It cautions that the comparison is not randomized and the arms are not a like-for-like control comparison. Statistical adjustment can sometimes account for measured differences, but it cannot automatically remove bias from unmeasured differences or changes that coincide with the intervention period. The analysis model, any covariate adjustment, and the approach to time-related changes are not reported in the registry record.

When event counts are binary, standard statistical models may be used to estimate differences or relative effects. The suitability of a model depends on how observations were collected, the number of events, the independence of observations, and the structure of the data. If multiple encounters from the same person or clustering by ED are present, the model may need to account for that dependence. Whether repeated observations or site clustering were relevant, and how they were handled, is not reported in the registry record.

Precision and statistical significance

A statistical test addresses compatibility between data and a specified null hypothesis under its assumptions. A p-value is not the probability that the null hypothesis is true, nor does it measure clinical or implementation importance. Estimates and confidence intervals are generally more informative for judging effect magnitude and precision. The registry record does not report a p-value or an interval for the primary outcome, so neither statistical significance nor precision can be assessed.

The sample-size material associated with the results is described as a planning illustration computed from the observed effect, not as the trial’s own design. It assumes a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is a stated fraction of the observed effect. Time-to-event illustrations give total events using the Schoenfeld approach, while other illustrations give participants per arm. These calculations are planning illustrations only. They are not observed power and do not establish that the study was designed around those assumptions. The registry record does not report the trial’s own sample-size justification.

Planning calculations depend on their assumed effect size, allocation, significance level, and statistical approximation. If the assumed effect is smaller, the planning requirement can change; if the real study differs from the assumed allocation or outcome structure, the illustration may not represent its actual design. Because the figures are derived from an observed effect, they describe hypothetical planning under stated assumptions rather than an independent guarantee of future performance. No numerical sample-size illustration results are reported in the registry record for interpretation.

Over-dispersion and model fit

General statistical context: over-dispersion occurs when observed variation is greater than a model expects. In count analyses, ignoring over-dispersion can make standard errors too small and confidence intervals too narrow. A model that accommodates extra variation may produce more realistic uncertainty. This is a general consideration only; the registry record does not report an over-dispersion assessment, nor does it provide enough outcome data to determine whether it would be relevant to the primary analysis.

Overall, the registry supplies the outcome description and selected design information, but not the statistical analysis details or primary outcome estimates. The appropriate interpretation is therefore limited to what the record states: the planned implementation question and a nonrandomized period comparison. Claims about effect size, confidence, or analytic robustness would require results and methods that are not reported in the registry record.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Baseline Evaluation Period Cohort", "IF Evaluation Period Cohort")
n      <- c(394, 362)
events <- c(2, 53)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Baseline Evaluation Period Cohort  394  2  0.5  0.1  1.8  0.1  1.8  0.2  1.8
ARM  IF Evaluation Period Cohort  362  53  14.6  11.2  18.7  11.4  18.7  11.4  18.7

11. Multiplicity, Missing Data and Analysis Populations

The registry lists 21 outcome measures and 2 analyses. It identifies implementation as the primary outcome and lists ED Organizational Readiness to Change Assessment (ORCA) Score as a secondary outcome. The available record does not explain how the 2 analyses relate to the outcome measures, whether additional outcomes were prespecified, or whether any multiplicity adjustment was planned or applied. Those details are not reported in the registry record.

Multiplicity arises when several outcomes, comparisons, or analytic choices are examined. The more opportunities there are to identify a nominally notable result, the greater the chance of at least one apparently strong finding arising by chance. Approaches to multiplicity can include prioritizing a primary outcome, adjusting statistical thresholds, or interpreting secondary results as exploratory. Which approach was used in this study is not reported in the registry record. Because primary and secondary results are not available, the record does not permit assessment of whether multiplicity affected interpretation.

The record also does not report how missing outcome data were handled, how many participants had complete data for each endpoint, or whether missingness differed by evaluation period. It does not describe whether the analyses used all enrolled participants, an eligible subset, or another analysis population. These details are important because exclusions and missing data can affect both the estimated outcome and its uncertainty.

The total enrollment of 1731 should not be assumed to equal the number analyzed for every outcome. The endpoint-specific denominators and handling of unavailable observations are not reported in the registry record. Without these details, the completeness and representativeness of the analysis populations cannot be assessed.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

The registry reports serious adverse event counts for two evaluation periods. In the Baseline Evaluation Period Cohort, 394 participants were listed as at risk, 0 as having a serious event, 0 as having another event in the separate count field, and 1 death was reported. In the IF Evaluation Period, 362 were listed as at risk, 0 as having a serious event, 0 as having another event in that field, and 2 deaths were reported.

These entries are counts, not estimates of comparative risk. The record does not report an analysis comparing the evaluation periods, confidence intervals, or details of the events. It also does not explain the definitions and relationship of the serious-event and other-event fields, how deaths were classified, or whether the periods had comparable follow-up and event ascertainment. The numbers therefore describe what the registry lists, but do not establish that one period was safer or less safe than the other.

The at-risk counts shown for these safety entries should not be treated as the number analyzed for the primary implementation outcome. The record does not report whether the safety and efficacy populations were defined in the same way. In addition, the nonrandomized period comparison can be affected by differences between cohorts and by changes over time. The safety figures are best read as descriptive registry counts with important context and analysis details not reported in the registry record.

13. What the Result Does, and Does Not, Mean

The record describes an implementation study evaluating standard dissemination practice and Implementation Facilitation (IF) in relation to ED-initiated buprenorphine/naloxone with referral for ongoing treatment. Its primary implementation question concerns the rate of that care process over 12 months. The study description also identifies patient engagement in formal addiction treatment at 30 days as an aim. These are related but distinct outcomes, and a result for one should not be taken as a result for the other.

The registry record does not report the primary outcome counts, rates, comparative estimate, confidence interval, or p-value. It is therefore not possible to determine from the record whether the implementation rate changed, how large a change might have been, or how precisely it was estimated. The absence of these results should not be interpreted as evidence of no effect; it indicates that the needed result is not reported in the registry record.

Even if a difference between the evaluation periods were available, the design would require cautious interpretation. The record lists no random allocation and warns that the comparison is not like-for-like. Differences in case mix, sites, practice, or context over time could contribute to an observed contrast. The registry record does not report whether such factors were measured or addressed.

The safety entries are also descriptive: the record lists zero serious events in each period, alongside deaths in both periods. Without event definitions, observation details, and a comparative analysis, these counts do not establish a safety difference. The enrollment total does not by itself resolve these uncertainties, because outcome-specific denominators and analysis populations are not reported.

In short, the registry record establishes the study’s implementation focus, broad design, and selected safety counts. It does not provide the results or methods needed to make a statistical judgment about the primary outcome, patient engagement, or comparative safety. Conclusions should remain within those limits.

14. Why This Trial Matters Statistically

This study raises a statistically important distinction between evaluating whether an implementation strategy is associated with uptake of a practice and evaluating whether patients subsequently engage in treatment. The registry describes both questions: ED-initiated BUP with referral as the primary implementation outcome, and patient engagement in formal addiction treatment at 30 days as an aim. Treating these as separate endpoints helps keep the interpretation aligned with what each measure captures.

It also illustrates why a comparator’s design matters as much as its label. Standard dissemination practice and IF are described as the approaches being evaluated, but the record identifies a baseline period and an IF evaluation period and cautions that they are not a like-for-like randomized comparison. A period contrast can be useful for describing implementation in context, yet it is more vulnerable to changes over time and differences between populations than a randomized comparison. The estimand and assumptions need to be explicit to support causal interpretation; those analytic details are not reported in the registry record.

Another statistical lesson is that enrollment alone does not convey precision. Readers need outcome counts, denominators, estimates, and uncertainty intervals to judge how informative a result is. The registry lists total enrollment of 1731 but does not report the primary outcome results or analysis populations. The number enrolled cannot substitute for endpoint-specific information.

Finally, the registry lists 21 outcome measures and 2 analyses, making transparent outcome prioritization and multiplicity handling relevant. Such details help readers distinguish confirmatory from exploratory evidence. Since the analysis plan and results are not reported in the registry record, this study is a reminder that design labels and study aims are not enough to evaluate a quantitative claim: the outcome definitions, comparison strategy, missing-data approach, and estimates with uncertainty are also needed.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for statistical interpretation is that the registry record does not report the primary outcome results. It gives the endpoint description and timeframe, but not the event counts, denominators, rate estimates, effect estimate, or uncertainty interval. Accordingly, the primary implementation question cannot be answered from the posted results.

The comparison is not randomized. The registry identifies baseline and IF evaluation periods and explicitly warns that the groups are not a like-for-like control comparison. This makes causal attribution difficult: secular changes, differences in participant mix, or changes in ED context could influence a period contrast. The registry record does not report whether adjustment or design measures addressed these possibilities.

Additional details needed to evaluate the endpoint are not reported in the registry record. These include eligibility for the primary outcome, the unit of analysis, the numerator and denominator definitions, handling of repeat encounters, and site-level structure. The record also does not report the analysis populations, missing-data methods, or outcome-specific denominators. Total enrollment cannot establish how many participants contributed to each analysis.

The record lists 21 outcome measures and 2 analyses but does not explain the analysis plan or multiplicity approach. It does not report the results for the secondary ORCA Score or the 30-day patient-engagement aim. Safety information is limited to counts, without event definitions, follow-up comparability, or a comparative analysis. These limitations concern the information available in the registry record; they do not establish what the investigators may have examined outside it.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Opioid Use Disorder in the Emergency Department: CTN 0069 — NCT03023930.
• Registry record last updated 2023-12-18; status last verified 2023-11.
• Results first posted 2023-02-21.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT03023930 is a completed study titled Opioid Use Disorder in the Emergency Department: CTN 0069, sponsored by Yale University. The registry lists enrollment of 1731, a start date of 2017-04-03, and a primary completion date of 2021-07-16. It describes a SINGLE GROUP study with no masking and allocation listed as NA.

The study evaluated standard dissemination practice and Implementation Facilitation in relation to ED-initiated BUP therapy with referral for ongoing MAT. The primary implementation outcome has a stated timeframe of 12 months. The record also describes patient engagement in formal addiction treatment at 30 days as an aim and lists ED Organizational Readiness to Change Assessment (ORCA) Score as a secondary outcome.

The registry cautions that the evaluation periods are not a randomized, like-for-like comparison. It reports safety counts, but does not report primary outcome estimates, uncertainty intervals, or key analytic details. As a result, the record supports a description of the study question and design, but not a statistical conclusion about the primary outcome.